Table 3.
AVR evaluation based on Definition 2, O2 versus O2 + iNO responders.
| Patients (N) | 100% O2 (% responders) | O2 + iNO (% responders) | |
|---|---|---|---|
| Group 1 PH | 338 | 6/316 (1.9) | 54/318 (16.9) |
| IPAH/FPAH | 171 | 4 (2.3) | 31 (18.7) |
| Prevalent | 152 | 4 | 28 |
| Incident | 19 | 0 | 3 |
| CTD‐PAH | 91 | 1 (1.1) | 14 (15.4) |
| Prevalent | 72 | 0 | 12 |
| Incident | 19 | 1 | 2 |
| Other‐PAHa | 76 | 1 (1.3) | 9 (11.8) |
| Prevalent | 67 | 1 | 8 |
| Incident | 9 | 0 | 1 |
Abbreviations: CTD, connective tissue disease; FPAH, familial pulmonary arterial hypertension; iNO, inhaled nitric oxide; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension.
a
Other‐PAH includes: DI‐PAH, HIV‐PAH, PH‐PAH, CHD‐PAH, PVOD‐PAH, PCH‐PAH.